1130 completed, 253 unknown, 198 recruiting, 187 terminated. 497 Phase 2, 385 Not applicable, 330 Phase 1, 281 Phase 3, 153 Phase 4.
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss Personalised Remapping Training, RSVP personalized remappi, Reading text in the wild with remapping - Macular Degeneration, Central Visual Impairment | Not applicable | Not yet recruiting | University of Minnesota | 100 | 2027-06-01 | 2026-07-07 |
| Non-invasive Ultrasound Retinal Stimulation for Vision Restoration Non-invasive ultrasound retinal stimulation Device - Age-Related Macular Degeneration, Retinitis Pigmentosa | Not applicable | Not yet recruiting | University of Southern California | 5 | 2027-01-10 | 2026-01-08 |
| MIND-AMD Study: a Multidisciplinary Investigation of Neuroretinal Damage in Age-related Macular Degeneration. Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD) | Not yet recruiting | IRCCS San Raffaele | 160 | 2027-01-02 | 2026-09-29 | |
| Prevalence of Age-Related Macular Degeneration in Assiut University Hospitals OCT - clear - Age-Related Macular Degeneration (AMD) | Not yet recruiting | Assiut University | 90 | 2027-01-01 | 2026-10-21 | |
| 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome N-acetylcysteine amide, Placebo - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Not yet recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-12-01 | 2026-07-01 |
| Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study Adaptive Optics Scanning Light Ophthalmoscopy, Microperimetry, Optical Coherence Tomography - Geographic Atrophy | Not applicable | Enrolling by invitation | University of Wisconsin, Madison | 10 | 2026-11-05 | 2026-10-26 |
| OCT Macula Biomarkers Before Silicone Oil Removal and Visual Outcome After Silicone Oil Removal Retinal Detachment, Macular Edema | Not yet recruiting | Assiut University | 30 | 2026-11-01 | 2026-10-08 | |
| Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration SCAI-005 0.04% 2drops TID, SCAI-005 0.08% 2drops TID, Placebo 2drops TID - wetAMD, Age Related Macular Degeneration | Phase 2 | Not yet recruiting | SCAI Therapeutics | 50 | 2026-11-01 | 2026-05-26 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05) OLN324, Ranibizumab - Wet Age-related Macular Degeneration | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 400 | 2026-10-15 | 2026-09-11 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04) OLN324, Aflibercept - Wet Age Related Macular Degeneration | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 500 | 2026-10-15 | 2026-09-11 |
| Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Not yet recruiting | Laboratoires Thea | 81 | 2026-10-05 | 2026-09-01 |
| Retinal and Choroidal Changes in Periodontal Disease Periodontal Diseases, Periodontal Diseases Inflammation | Not yet recruiting | Zeliha Başak Çakır Erdil | 80 | 2026-10-01 | 2026-10-05 | |
| Photobiomodulation Laser for Reticular Pseudodrusen in Age-Related Macular Degeneration Photobiomodulation Therapy, Sham Photobiomodulation - AMD - Age-Related Macular Degeneration | Not applicable | Not yet recruiting | Fondazione G.B. Bietti, IRCCS | 67 | 2026-10-01 | 2026-09-04 |
| A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome Placebo, NPI-001 - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-10-01 | 2026-10-13 |
| Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa ULREA-PVS-NP - Retinitis Pigmentosa (RP) | Phase 1 | Recruiting | Kyushu University | 21 | 2026-10-01 | 2026-10-07 |
| Iopidine to Decrease Intraocular Pressure Rise After Injections Apraclonidine 1.0% ophthalmic solution - Macular Degeneration, Diabetic Retinopathy | Phase 4 | Not yet recruiting | Retina Consultants of Delmarva | 120 | 2026-10-01 | 2026-10-23 |
| Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT) RTx-015, Sham Control - Retinitis Pigmentosa (RP), Inherited Retinal Diseases | Phase 2 / Phase 3 | Recruiting | Ray Therapeutics, Inc. | 60 | 2026-10-01 | 2026-10-28 |
| A Case-Control Study Revealing Intraocular Microenvironment Characteristics in Patients With Ocular Diseases Based on Multi-Omics Analysis Not applicable- observational study - Age- Related Macular Degeneration, Diabetic Retinopathy | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 150 | 2026-10-01 | 2026-10-27 | |
| An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Vonaprument - Geographic Atrophy | Phase 3 | Not yet recruiting | Annexon, Inc. | 605 | 2026-09-30 | 2026-09-08 |
| Evaluation of PAN-90806 Eye Drops in Healthy Subjects PAN-90806 Ophthalmic Solution, Vehicle Ophthalmic Solution - Wet Age Related Macular Degeneration, Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 | Not yet recruiting | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | 20 | 2026-09-30 | 2026-08-14 |
Showing 20 of 2013. Sign in to see all of them.
Macular Degeneration (1171) · Macular Edema (418) · Retinitis Pigmentosa (268) · Geographic Atrophy (178) · Diabetic Retinopathy (160) · Retinal Vein Occlusion (155) · Choroidal Neovascularization (138) · Retinal Diseases (136) · Eye Diseases (99) · Wet Macular Degeneration (93) · Vision Disorders (89) · Diabetes Mellitus (66) · Stargardt Disease (66) · Glaucoma (52)
Eye Diseases (1914) · Retinal Diseases (1877) · Macular Degeneration (527) · Eye Diseases, Hereditary (422) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (380) · Pathological Conditions, Signs and Symptoms (370) · Genetic Diseases, Inborn (369) · Cardiovascular Diseases (308) · Vascular Diseases (307) · Retinal Dystrophies (277) · Nervous System Diseases (219) · Uveal Diseases (218) · Endocrine System Diseases (208) · Pathologic Processes (198)
Ranibizumab (263) · aflibercept (151) · Bevacizumab (81) · salicylhydroxamic acid (62) · Dexamethasone (51) · Calcium Dobesilate (40) · Triamcinolone Acetonide (34) · Verteporfin (32) · pegaptanib (26) · brolucizumab (22) · Triamcinolone (21) · Tomography, Optical Coherence (18) · Lutein (15) · Photochemotherapy (14) · Intravitreal Injections (13)
National Eye Institute (NEI) (90) · Novartis Pharmaceuticals (67) · Allergan (38) · Bayer (38) · Medical University of Vienna (28) · Genentech, Inc. (26) · Johns Hopkins University (25) · Notal Vision Ltd. (21) · Alcon Research (20) · Hoffmann-La Roche (16) · Pfizer (16) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (15) · Duke University (14) · University of Sao Paulo (13) · GlaxoSmithKline (12)
United States (908) · France (193) · Germany (189) · United Kingdom (176) · Canada (133) · Italy (130) · Australia (113) · China (113) · Spain (104) · Austria (103) · Israel (88) · Hungary (72) · Switzerland (71) · Poland (65) · Czechia (63)
Emily Y Chew, M.D. (9) · Pablo Velazquez-Martin, MD (8) · Peter A Campochiaro, MD (6) · Jennifer Henrick, RN, MS (5) · Mohamed Genead, MD (5) · Peter Campochiaro, MD (5)
PMID 37314061, PMID 37702300, PMID 32374423, PMID 32573764, PMID 40547876, PMID 22281388, PMID 25458728, PMID 30957581, PMID 32844399, PMID 34934034, PMID 39758130, PMID 23049090, PMID 23084240, PMID 23706949, PMID 25677668, PMID 30194931, PMID 33206392, PMID 33331670, PMID 35085502, PMID 36246941, PMID 36912792, PMID 37261916, PMID 39102242, PMID 39207600, PMID 11297486, PMID 15808240, PMID 17021318, PMID 17021319, PMID 19255158, PMID 19365036, PMID 19506188, PMID 20189654, PMID 20378094, PMID 20683380, PMID 20688734, PMID 20920825, PMID 21296824, PMID 21320967, PMID 21546089, PMID 21794843, PMID 22234714, PMID 22559899, PMID 22562517, PMID 22761263, PMID 22965590, PMID 23009891, PMID 23361508, PMID 23415775, PMID 23453513, PMID 23668681
2014 (12), 2019 (11), 2018 (7), 2025 (6), 2009 (5), 2017 (5), 2015 (4), 2016 (4), 2005 (2), U10EY014231 (2), U10EY018817 (2), U10EY024527 (2), 1UG1EY033293 (1), 2023 (1), I01RX004563 (1)